• Clinical data showed TAK was rapidly absorbed with

  2022-02-07

  

  Clinical data showed TAK-875 was rapidly absorbed with a half-life of 28-30h and clearance primarily through glucouronidation in the liver with minimal urinary clearance [30]. TAK-875 made the glycosylated hemoglobin (HbA1c) levels fall significantly from baseline after 24-week administration in onc

• MMV s distinct mode of inhibition

  2022-02-05

  

  MMV019313's distinct mode of inhibition addresses key impediments in the development of PfFPPS/GGPPS inhibitors as antimalarial drugs. First, it is the first non-bisphosphonate inhibitor of Plasmodium FPPS/GGPPS with drug-like physicochemical properties satisfying the “Rule of 5” (Van Voorhis et al.

• GCIPs are highly conserved Ca

  2022-02-05

  

  GCIPs are highly conserved Ca2+-binding proteins first discovered in the frog [42] and later in teleost [9]. With regard to gene structure, sequence conservation, and function, GCIPs are evolutionarily related to the GCAPs. The GCIP genes have acquired an additional intron in the N-terminal region w

• Quinidine receptor At days and hours after MI

  2022-02-05

  

  At 21 days and 24 hours after MI, the protein expressions of active JNK1 (P protein Quinidine receptor of p38 was down-regulated only at 21 days after MI (P Discussion This study demonstrates the role of GSTP1 in HF by inhibiting the TRAF2-induced MAPK activation and the potent inhibitory effect

• The fact that GSK recognition

  2022-02-05

  

  The fact that GSK-3 recognition of its substrate involves pre-phosphorylation supports the rational for using synthetic phosphorylated peptides as substrate competitive inhibitors [57]. Phosphorylated peptides derived from the N-terminal pseudosubstrate sequence of GSK-3β were very weak inhibitors o

• The rat model was validated with another

  2022-02-04

  

  The rat model was validated with another agonist of GPR109A, acipimox. Acipimox has been shown to induce vasodilatation in man, by a mechanism dependent on the release of vasodilator prostaglandins (Edlund et al., 1990, Pontiroli et al., 1992). Acipimox is a weaker agonist of the GPR109A receptor (L

• Reports of hyperlocomotion after administration of ALX coupl

  2022-02-04

  

  Reports of hyperlocomotion after administration of ALX-5407 [27] coupled with the lack of hyperlocomotion after administration of SSR504734, a non-sarcosine, long-residence time, competitive inhibitor [19], suggested that the GlyT1 inhibitor chemotype may impact OP. Furthermore, a compound with a co

• In experiments using D to displace binding of

  2022-02-04

  

  In experiments using D22 to displace binding of specific high-affinity radioligands for DAT, NET, and SERT in mouse Clindamycin Phosphate tissue, we observed a ranking with D22 displacement efficiency in the order of DAT > SERT > NET (IC50 values being ~ 11 (DAT), 26 (SERT), and 101 (NET) µM; Fig.

• br Treatment KD is currently the treatment

  2022-02-04

  

  Treatment KD is currently the treatment of choice for GLUT1-DS. It is a high-fat, carbohydrate-restricted diet that mimics the metabolic state of fasting; so, the KD relies an exogenous rather than body fat for ketone production, thus maintaining ketosis without weight loss. As the developing br

• L Family Leguminosae widely distributed in tropical

  2022-02-04

  

  L. (Family Leguminosae) widely distributed in tropical and subtropical regions of the world. As a medicinal and edible plant, it is widely used in Asia, especially in China, Korea, Japan and India. It was first recorded in Shen Nong Ben Cao Jing (神农本草经), and was described having the effect of cleari

• In the present study we

  2022-02-03

  

  In the present study we set out to discover new non-steroidal SEGRA and to analyse their mechanism of function. Towards this goal we initiated a virtual screening (VS) approach, utilizing structure-based pharmacophore modeling, in silico docking and molecular dynamics (MD) simulations. Our pharmacop

• Andexanet alfa works as a

  2022-02-03

  

  Andexanet alfa works as a decoy for the FXa inhibitor to bind to irreversibly. The recently completed ANDEXA-4 trial, which was a prospective, open-label, single group study, found that patients achieved good or excellent hemostasis in 82% of subjects [, , ]. There was an overall 10% thromboembolic

• br Introduction Currently HIV infection treatment

  2022-02-03

  

  Introduction Currently, HIV-1 infection treatment guidelines adopted in USA and EU provide for the simultaneous administration of three antiretroviral drugs (HAART “Highly Active Anti-Retroviral Therapy”) in severely compromised patients [[1], [2], [3]]. Coupling at least two different mechanisms

• Evidence demonstrating the interplay between hypoxia

  2022-02-01

  

  Evidence demonstrating the interplay between hypoxia and the dynamics of histone methylation is mounting [15], [43]. For example, hypoxia leads to an increase in H3K4me3 by inhibiting their responsible demethylase [44]. Hypoxia also leads to an increase in H3K9me2 by upregulating the methyltransfera

• In C elegans KDM A appears to be involved in

  2022-02-01

  

  In C. elegans, KDM4A appears to be involved in H3K36me3 reduction on the X chromosome, suggesting that this protein has a relevant role in germ cell development (Figure 2A) (47). In addition, in HeLa cells, KDM4A is associated with the repression of the achaete-scute complex homologue 2 (ASCL2) gene

14971 records 421/999 page Previous Next First page 上5页 421422423424425 下5页 Last page